Darunavir combination formulations

Abstract

This invention relates to solid oral dosage forms of the HIV inhibitor Darunavir and/or a pharmaceutically acceptable salt or solvate thereof, and combination formulations thereof.

1 . An oral dosage form comprising about 0.4 to 0.6% by weight (w/w) of a lubricant, about 3% by weight (w/w) of a disintegrant, 17 to 20% by weight (w/w) of silicon dioxide loaded with GS-9350 corresponding to a total amount of about 150 mg free form equivalent of GS-9350 and about 50 to 60% by weight (w/w) of darunavir granulate, said darunavir granulate consisting of darunavir and/or a pharmaceutically acceptable salt or solvate thereof, Hypromellose and any residual water from the granulation. 
     
     
         2 . An oral dosage form according to  claim 1 , wherein the silicon dioxide loaded with GS-9350 is colloidal silicon dioxide. 
     
     
         3 . An oral dosage form according to  claim 1 , wherein the Hypromellose is Hypromellose 2910 15 mPa·s. 
     
     
         4 . An oral dosage form according to  claim 1 , comprising about 0.5% by weight (w/w) of a lubricant 
     
     
         5 . An oral dosage form according to  claim 1 , wherein the desintegrant is polyplasdone XL-10 and the lubricant is magnesium stearate 
     
     
         6 . An oral dosage form according to  claim 1 , comprising about 800 mg free form equivalent of Darunavir. 
     
     
         7 . A process for preparing an oral dosage form as claimed in  claim 1  which comprises the steps of:
 Providing granulated darunavir by; mixing water and Hypromellose, spraying this first mixture on a powder of darunavir and/or a pharmaceutically acceptable salt or solvate thereof, and drying the so obtained darunavir granulate 
 Providing a second mixture comprising microcrystalline cellulose, silicon dioxide loaded with GS-9350, a disintegrant, 
 Adding granulated darunavir to the mixture and subsequent dry-blending 
 Adding a lubricant and mixing until homogeneous, 
 Compressing the mixture to provide the oral dosage form, said oral dosage form then being optionally film-coated. 
 
     
     
         8 . A process for preparing an oral dosage form according to  claim 7 , wherein the silicon dioxide loaded with GS-9350 is colloidal silicon dioxide. 
     
     
         9 . An oral dosage form as claimed in  claim 1  for use in medicine. 
     
     
         10 . An oral dosage form as claimed in  claim 1  for use in the treatment of HIV infection. 
     
     
         11 . A method for the treatment of an HIV infection in a subject which comprises administering to the subject an effective amount of an oral dosage form as claimed in  claim 1 .